Digital Twin–Assisted Risk Disclosure in Adults Undergoing Elective Bronchoscopy: Multicenter Randomized Controlled Trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Utilizing Digital Twin Technology for Risk Communication in Adults Undergoing Elective Bronchoscopy: A Multicenter Randomized Controlled Study

  • By

  • Mingming Deng

  • Weidong Xu

  • Fei Tang

  • Hong Chen

  • Zhen Yang

  • Feng Wang

  • Nan Zhang

  • Haihong Wu

  • Jia Li

  • Ziwen Zheng

  • Sinan Wu

  • Gang Hou

  • October 6, 2026

Share

  • 1

    Informed consent for elective bronchoscopy requires patients to understand risks, benefits, and alternatives while addressing their concerns.

  • 2

    Conventional consent methods may hinder comprehension due to complex terminology and varying clinician explanations.

  • 3

    Digital consent methods, including multimedia, have shown improved comprehension but inconsistent effects on anxiety and satisfaction.

  • 4

    Randomized studies indicate that detailed risk disclosure can increase anxiety, while multimedia aids may enhance satisfaction without affecting anxiety.

  • 5

    Virtual reality and music interventions during bronchoscopy have mixed results on anxiety and comfort, highlighting the need for tailored approaches.

Original Source(s)

Digital Twin–Assisted Risk Disclosure in Adults Undergoing Elective Bronchoscopy: Multicenter Randomized Controlled Trial

  • by Mingming Deng, Weidong Xu, Fei Tang, Hong Chen, Zhen Yang, Feng Wang, Nan Zhang, Haihong Wu, Jia Li, Ziwen Zheng, Sinan Wu, Gang Hou

  • October 6, 2026

Related Content

The drugs and devices have been on the market for years. But FDA-ordered studies still aren’t done.

“Doctors rely on this evidence, patients rely on this evidence, and if that evidence is not there, it’s going to lead to a lot of uncertainty."

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.

Autonomous Oxygen Titration for Maintaining Normoxemia in Acutely Ill Adults: The SAVE-O 2 AI Randomized